Urology-Textbook.com

Up-to-date urology insights from Dirk Manski

 You are here: Urology Textbook > Drugs in Urology > Anticholinergics > Tolterodine

Tolterodine: Mechanism of Action, Side Effects, Contraindications, and Dosage

Mechanism of Action

Tolterodine is a lipophilic tertiary amine with anticholinergic effects on muscarinic receptors. Tolterodine has a certain organ selectivity, leading to a stronger effect on the bladder than on the salivary glands.

The inhibition of M3 receptors with Tolterodine reduces smooth muscle detrusor contraction, increases functional bladder capacity, and alleviates urgency symptoms. Tolterodine is used to treat overactive bladder, urge incontinence, and neurogenic lower urinary tract dysfunction.

Pharmacokinetics of Tolterodine:

There is a pronounced hepatic metabolism to active metabolites by cytochrome CYP2D6 after oral absorption. Half-life 3–10 hours (depending on CYP2D6 activity and release formulation), mainly renal excretion of the metabolites.

Side Effects of Tolterodine

Muscarinic receptors are present in numerous organs. M3 receptors are mainly found in smooth muscle and glands. Tolterodine has a certain organ selectivity and may lead to fewer side effects compared to other anticholinergics.

Eye:
Gastrointestinal tract:
Heart:
CNS:
Skin:

Drug Interactions

Increased anticholinergic effect with antiparkinson drugs, antihistamines, antipsychotics, and tricyclic antidepressants. Amplification of the tachycardic effect of sympathomimetic medications. Propiverine mitigates the effects of gastrointestinal prokinetics. Ketakonazole and macrolid antibiotics may increase the plasma concentration of Tolterodine.

Contraindications of Tolterodine

Dosage of Tolterodine:

Depending on the effect (and side effects), either 1–2 mg twice daily or a extended-release formulation 2–4 mg once daily.






Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

References

Ouslander 2004 OUSLANDER, J. G.: Management of overactive bladder.
In: N Engl J Med
350 (2004), Nr. 8, S. 786–99

Yoshimura und Chancellor 2002 YOSHIMURA, N. ; CHANCELLOR, M. B.: Current and future pharmacological treatment for overactive bladder.
In: J Urol
168 (2002), Nr. 5, S. 1897–913



  Deutsche Version: Nebenwirkungen und Dosierung von Tolterodin

Urology-Textbook.com – Choose the Ad-Free, Professional Resource

This website is designed for physicians and medical professionals. It presents diseases of the genital organs through detailed text and images. Some content may not be suitable for children or sensitive readers. Many illustrations are available exclusively to Steady members. Are you a physician and interested in supporting this project? Join Steady to unlock full access to all images and enjoy an ad-free experience. Try it free for 7 days—no obligation.

-->